MD Anderson breaks ground on new Sugar Land location
Business Announcement
Updates every hour. Last Updated: 1-May-2025 11:08 ET (1-May-2025 15:08 GMT/UTC)
SUGAR LAND, Texas ― The University of Texas MD Anderson Cancer Center today broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range of cancer services and MD Anderson’s unparalleled patient experience closer to those living in Southwest Houston and the surrounding areas.
As warehouses go, nuclei are more like libraries than bank vaults. Too many cellular components need access to the genome to lock it down like Fort Knox. Instead, large groupings of more than 1,000 individual protein molecules called nuclear pore complexes (NPCs) pepper the dividing membrane, serving as gateways for materials and messages entering and exiting the nucleus.
While the basic need for this shuttle service is constant, scientists have shown that cells dynamically adjust their amounts of NPCs like a retail store opening more or fewer checkout lines throughout the day. Scientists at Sanford Burnham Prebys published findings March 31, 2025, in Cell Reports revealing the results of screening the entire human genome to find factors influencing how many NPCs are assembled.A new study on the genetic causes of the PTEN Hamartoma Tumour Syndrome (PHTS) has found that inhibitors of the PI3ka pathway, commonly used as anticancer drugs, are also effective against this disease, reducing the extent of vascular malformations and lesion-associated pain in animal models. The research, led by Dr. Sandra Castillo, Dr. Eulàlia Baslega and Dr. Mariona Graupera, from the SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, and the Josep Carreras Leukaemia Research Institute, respectively, suggests the repurposing of these drugs may offer a new hope for PHTS patients, especially at younger ages. The research has been published in Cancer Discovery, a journal of the American Association for Cancer Research.
Researchers from Prof. Yardena Samuels’s lab manipulated cancer cells into making themselves visible to the immune system, creating a new approach that gives hope to patients with previously untreatable disease
This study explores the relationship between gallstones, cholecystectomy, and cancer risk through both observational and Mendelian randomization (MR) methods. The research aims to clarify the inconsistent findings from previous studies regarding the association of gallstones and cholecystectomy with various types of cancers, particularly in Chinese adults.
Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period. These findings from the API-CAT trial were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).
Investigators at Mass General Brigham have uncovered how resistance to chemotherapies may occur in some cancers. Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study found that mutations to VPS35, a key player in this pathway, can prevent chemotherapy-induced cell death. These results, published in Nature, could help pinpoint treatment-resistant tumors.
The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, Fellow of the AACR Academy, as the AACR President-Elect for 2025-2026. Flaherty will become President-Elect on Monday, April 28, during the AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2025 in Chicago, Illinois and will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego, California.